| Generic name | Nelarabine |
| Pronunciation | Nel-AY-re-been |
| Brand name(s), other common name(s) | Arranon® |
| Drug type | Antimetabolite |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Nelarabine is FDA approved to treat people who have relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma following treatment with at least two chemotherapy regimens.
Side effects needing medical attention
Seizures; excessive sleepiness; numbness and tingling in the hands, fingers, feet or toes; problems with fine motor skills such as buttoning clothes; unsteadiness while walking; increased tripping while walking; weakness when getting out of a chair or walking up stairs; fever; signs of infection; bruising easily or unusual bleeding; difficulty breathing; fatigue; paleness.
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.